Pfizer (PFE) Land & Improvements (2009 - 2011)
Pfizer (PFE) posted quarterly Land & Improvements of $747.0 million for Q4 2011, down 5.56% year-over-year from $791.0 million in Q4 2010, and down 5.56% quarter-over-quarter from $791.0 million in Q4 2010.
Pfizer (PFE) Land & Improvements (2009 - 2011) Analysis & Trends
Pfizer (PFE) has reported Land & Improvements for 3 consecutive years, with $747.0 million the latest figure, recorded in Q4 2011.
- In Q4 2011, Land & Improvements fell 5.56% year-over-year to $747.0 million; the TTM figure through Dec 2011 stood at $747.0 million (down 5.56% YoY), while the FY2011 annual figure was $747.0 million, down 5.56% from the prior year.
- Land & Improvements retreated to $747.0 million in Q4 2011 per PFE's latest filing, from $791.0 million in the prior quarter.
- Across five years, Land & Improvements topped out at $937.0 million in Q4 2009 and bottomed at $747.0 million in Q4 2011.
- Historically, Land & Improvements has averaged $825.0 million across 3 years, with a median of $791.0 million in 2010.
- Annual changes were most pronounced in 2010 — Land & Improvements fell 15.58% — and 2011, when it dropped 5.56%.
- Pfizer's Land & Improvements stood at $937.0 million in 2009, then slipped by 15.58% to $791.0 million in 2010, then dropped by 5.56% to $747.0 million in 2011.
- Business Quant data shows PFE's Land & Improvements at $747.0 million in Q4 2011, $791.0 million in Q4 2010, and $937.0 million in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 747.00 Mn |
| Dec 31, 2010 | 791.00 Mn |
| Dec 31, 2009 | 937.00 Mn |